Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

The many faces of Janus kinase.

Seavey MM, Dobrzanski P.

Biochem Pharmacol. 2012 May 1;83(9):1136-45. doi: 10.1016/j.bcp.2011.12.024. Epub 2011 Dec 24. Review.

PMID:
22209716
2.

JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.

Treliński J, Robak T.

Curr Med Chem. 2013;20(9):1147-61.

PMID:
23317159
3.

Advances in the discovery of selective JAK inhibitors.

Menet CJ, Rompaey LV, Geney R.

Prog Med Chem. 2013;52:153-223. doi: 10.1016/B978-0-444-62652-3.00004-1. Review.

PMID:
23384668
4.

JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.

Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, Hricik T, Bhagwat N, McKenney AS, Papalexi E, Abdel-Wahab O, Rampal R, Marubayashi S, Chen JJ, Romanet V, Fridman JS, Bromberg J, Teruya-Feldstein J, Murakami M, Radimerski T, Michor F, Fan R, Levine RL.

Cancer Discov. 2015 Mar;5(3):316-31. doi: 10.1158/2159-8290.CD-14-0736. Epub 2015 Jan 8.

5.

Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro.

Wilson GS, Tian A, Hebbard L, Duan W, George J, Li X, Qiao L.

Cancer Lett. 2013 Dec 1;341(2):224-30. doi: 10.1016/j.canlet.2013.08.009. Epub 2013 Aug 11.

PMID:
23941832
6.

JAK2 the future: therapeutic strategies for JAK-dependent malignancies.

LaFave LM, Levine RL.

Trends Pharmacol Sci. 2012 Nov;33(11):574-82. doi: 10.1016/j.tips.2012.08.005. Epub 2012 Sep 17. Review.

PMID:
22995223
7.

17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells.

Wang Y, Ma X, Yan S, Shen S, Zhu H, Gu Y, Wang H, Qin G, Yu Q.

Cancer Res. 2009 Sep 15;69(18):7302-10. doi: 10.1158/0008-5472.CAN-09-0462. Epub 2009 Aug 25.

8.

Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.

Koppikar P, Abdel-Wahab O, Hedvat C, Marubayashi S, Patel J, Goel A, Kucine N, Gardner JR, Combs AP, Vaddi K, Haley PJ, Burn TC, Rupar M, Bromberg JF, Heaney ML, de Stanchina E, Fridman JS, Levine RL.

Blood. 2010 Apr 8;115(14):2919-27. doi: 10.1182/blood-2009-04-218842. Epub 2010 Feb 12.

10.

Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.

Bhagwat N, Levine RL, Koppikar P.

Int J Hematol. 2013 Jun;97(6):695-702. doi: 10.1007/s12185-013-1353-5. Epub 2013 May 14. Review.

PMID:
23670175
11.

JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms.

Parampalli Yajnanarayana S, Stübig T, Cornez I, Alchalby H, Schönberg K, Rudolph J, Triviai I, Wolschke C, Heine A, Brossart P, Kröger N, Wolf D.

Br J Haematol. 2015 Jun;169(6):824-33. doi: 10.1111/bjh.13373. Epub 2015 Mar 30.

PMID:
25824483
12.

New generation small-molecule inhibitors in myeloproliferative neoplasms.

Passamonti F, Maffioli M, Caramazza D.

Curr Opin Hematol. 2012 Mar;19(2):117-23. doi: 10.1097/MOH.0b013e32834ff575. Review.

PMID:
22227528
13.

Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.

Roskoski R Jr.

Pharmacol Res. 2016 Sep;111:784-803. doi: 10.1016/j.phrs.2016.07.038. Epub 2016 Jul 26. Review.

PMID:
27473820
14.

Targeting JAK kinase in solid tumors: emerging opportunities and challenges.

Buchert M, Burns CJ, Ernst M.

Oncogene. 2016 Feb 25;35(8):939-51. doi: 10.1038/onc.2015.150. Epub 2015 May 18. Review.

PMID:
25982279
15.

The JAK-STAT pathway: a therapeutic target in hematological malignancies.

Ferrajoli A, Faderl S, Ravandi F, Estrov Z.

Curr Cancer Drug Targets. 2006 Dec;6(8):671-9. Review.

PMID:
17168672
16.

The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia.

Lee HJ, Daver N, Kantarjian HM, Verstovsek S, Ravandi F.

Clin Cancer Res. 2013 Jan 15;19(2):327-35. doi: 10.1158/1078-0432.CCR-12-2087. Epub 2012 Dec 3. Review.

17.

Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.

Dymock BW, See CS.

Expert Opin Ther Pat. 2013 Apr;23(4):449-501. doi: 10.1517/13543776.2013.765862. Epub 2013 Feb 1. Review.

PMID:
23367873
18.

Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.

Quintás-Cardama A, Verstovsek S.

Clin Cancer Res. 2013 Apr 15;19(8):1933-40. doi: 10.1158/1078-0432.CCR-12-0284. Epub 2013 Feb 13. Review.

19.

Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.

Liu PC, Caulder E, Li J, Waeltz P, Margulis A, Wynn R, Becker-Pasha M, Li Y, Crowgey E, Hollis G, Haley P, Sparks RB, Combs AP, Rodgers JD, Burn TC, Vaddi K, Fridman JS.

Clin Cancer Res. 2009 Nov 15;15(22):6891-900. doi: 10.1158/1078-0432.CCR-09-1298. Epub 2009 Nov 3.

20.

Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms.

Stein BL, Crispino JD, Moliterno AR.

Curr Opin Oncol. 2011 Nov;23(6):609-16. doi: 10.1097/CCO.0b013e32834d1b22. Review.

PMID:
21993415

Supplemental Content

Support Center